Does UnitedHealthcare Cover GLP-1? Diabetes, Weight Loss, Medicare

UnitedHealthcare does cover GLP-1 medications, but whether your prescription is paid for depends on three things: the diagnosis it’s written for, the specific plan you’re on, and, for weight-loss use, whether your employer elected that benefit. GLP-1s prescribed for type 2 diabetes are generally covered under the pharmacy benefit with prior authorization. GLP-1s prescribed for weight loss are only covered if your plan includes weight-loss drug benefits and you meet clinical criteria.

If the Prescription Is for Type 2 Diabetes

This is the straightforward path. UnitedHealthcare’s diabetes GLP-1 program covers Mounjaro (tirzepatide), Ozempic (semaglutide injection), Rybelsus (semaglutide tablets), and Trulicity (dulaglutide).1UHC Provider. Prior Authorization – Diabetes Agents GLP-1 Receptor Agonists

Prior authorization requires documentation of a type 2 diabetes diagnosis. That can be an A1C of 6.5% or higher, a fasting plasma glucose of 126 mg/dL or higher, or other standard diagnostic criteria. For a diagnosis made more than two years ago, medical records confirming it are sufficient. Approvals run for 12 months.1UHC Provider. Prior Authorization – Diabetes Agents GLP-1 Receptor Agonists

Step therapy was removed from this program in April 2024, so you no longer have to try other diabetes medications first. Two limits to know: the diabetes program excludes use for weight loss, and Victoza (liraglutide) is typically excluded entirely.1UHC Provider. Prior Authorization – Diabetes Agents GLP-1 Receptor Agonists

If the Prescription Is for Weight Loss

Wegovy (semaglutide injection and tablet), Zepbound (tirzepatide), and Saxenda (liraglutide) are the weight-loss GLP-1s on UnitedHealthcare’s radar. The threshold question is whether your plan covers weight-loss drugs at all. Many employer groups do not. A 2024 Kaiser Family Foundation survey found that only 18% of employers offer GLP-1 coverage specifically for weight loss.2NFP. GLP-1 Discrimination Considerations for Employer Plans Check your benefit plan documents or call the number on your member ID card before anything else.

If your plan does include the benefit, all three drugs require prior authorization and you must meet the clinical criteria set in UnitedHealthcare’s May 2026 policy update:

  • BMI of 30 or higher, or BMI of 27 or higher with a weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidemia, or sleep apnea. Pediatric patients must be above the 95th percentile for BMI.
  • Use alongside diet, exercise, behavioral support, or a community-based program.
  • Age 12 or older for Wegovy and Saxenda; older than 16 for Zepbound.3UHC Provider. Prior Authorization – Weight Loss

Step therapy is not required for weight-loss GLP-1s under commercial plans, so you don’t have to try other weight-loss drugs first.3UHC Provider. Prior Authorization – Weight Loss

Initial authorization lasts five months for Wegovy, six months for Zepbound, and four months for Saxenda. To renew, you’ll need to show a clinical response — typically at least 5% weight loss from baseline — and continued lifestyle participation. Renewals run for 12 months.3UHC Provider. Prior Authorization – Weight Loss

Required Coaching Programs

A growing share of employers that cover weight-loss GLP-1s now require participation in a behavioral coaching program as a condition of coverage. UnitedHealthcare reports that more than one-third of employers offering GLP-1 coverage mandate it, up from 10% the prior year.4UHC. Sustainable Weight Management UnitedHealthcare’s vehicle is the Total Weight Support program, which pairs medication access with coaching through either Real Appeal Rx or WeightWatchers for Business, depending on employer selection.5UHC. Total Weight Support For members in these plans, monthly coaching sessions are built into the prior authorization requirements.

Other Diagnoses That Open Coverage

If your plan excludes weight-loss drugs, you may still have a path. Wegovy and Zepbound carry additional covered indications:

  • Wegovy is covered for reducing the risk of major cardiovascular events in patients with established cardiovascular disease.
  • Wegovy is covered for metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis. This indication does not require meeting a specific BMI threshold.
  • Zepbound is covered for moderate to severe obstructive sleep apnea.3UHC Provider. Prior Authorization – Weight Loss

If one of these conditions applies to you, a denial on the weight-loss track doesn’t necessarily end the matter. The same drug prescribed for a different FDA-approved condition may be covered on different criteria.6Everyday Health. I Lost Access to My GLP-1 Weight Loss Drug What Now

UnitedHealthcare Medicare Plans

Medicare has not historically covered weight-loss drugs. That changes temporarily through the Medicare GLP-1 Bridge program, a nationwide demonstration running from July 1, 2026, through December 31, 2026. It covers Wegovy (injection and tablet), Zepbound (KwikPen only), and Foundayo (orforglipron, approved in April 2026).7Medicare.gov. Weight Loss Drugs

The copayment is $50 per monthly supply. Eligibility is tied to BMI and comorbidities:

  • BMI 35 or higher: eligible without additional conditions.
  • BMI 30 to 34.99: eligible with one qualifying condition such as diastolic heart failure, uncontrolled hypertension, chronic kidney disease (stage 3a or higher), prediabetes, history of heart attack or stroke, or symptomatic peripheral artery disease.
  • BMI 27 to 29.99: eligible with prediabetes, history of heart attack or stroke, or symptomatic peripheral artery disease.7Medicare.gov. Weight Loss Drugs

If you already get GLP-1s through standard Part D for diabetes, or you have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease, you aren’t eligible for the Bridge program because those indications fall under regular Part D.7Medicare.gov. Weight Loss Drugs The Bridge operates outside normal Part D structures — Humana handles administration centrally — and the $50 copay doesn’t count toward Part D deductibles or out-of-pocket limits.8CMS. Medicare GLP-1 Bridge

UnitedHealthcare Medicaid Plans

Medicaid coverage is driven by state decisions. As of January 2026, only 13 state Medicaid programs cover GLP-1s for obesity under fee-for-service, down from 16 in October 2025. California, New Hampshire, Pennsylvania, and South Carolina dropped obesity coverage in that window due to budget pressures.9KFF. Medicaid Coverage of and Spending on GLP-1s

State Medicaid programs must cover GLP-1s for diabetes, cardiovascular risk reduction (Wegovy), and moderate to severe obstructive sleep apnea (Zepbound). Obesity coverage is optional, and prior authorization is typically required where it exists.9KFF. Medicaid Coverage of and Spending on GLP-1s

Formulary rules can also vary within UnitedHealthcare Medicaid lines. In Massachusetts, the Community Plan for Senior Care Options and One Care made Zepbound the preferred weight-loss GLP-1 and removed Wegovy and Saxenda from the preferred drug list. New users seeking Zepbound must try phentermine first. Wegovy remains available in that plan only for cardiovascular risk reduction in patients with established heart disease.10UHC Provider. MA Medicaid Zepbound Phentermine

Two Boundary Cases to Know

North Dakota fully insured essential health benefit plans apply a stricter initial BMI threshold for Wegovy and Zepbound: 40 or higher (or above the 120th percentile of the 95th percentile for pediatric patients). The exception is Wegovy for MASH, which still has no specific BMI requirement.3UHC Provider. Prior Authorization – Weight Loss

Compounded semaglutide and tirzepatide from telehealth services and compounding pharmacies are not addressed in UnitedHealthcare’s weight-loss policy. The policy covers only FDA-approved brand-name products and their authorized generic equivalents.3UHC Provider. Prior Authorization – Weight Loss

If Your Coverage Is Denied

For Medicare Part D members, the process starts with a formal coverage determination. If that’s denied, you or your doctor can file a Level 1 redetermination within 65 days. Standard decisions come within seven calendar days; expedited reviews for urgent health situations come within 72 hours. A denial at Level 1 can be escalated to an Independent Review Entity for Level 2. You can also request a formulary exception if the drug isn’t on your plan’s list, or a cost-sharing exception to move to a lower tier, provided your doctor supplies medical necessity documentation.11UHC. Prescription Drug Appeals

For commercial plan members, UnitedHealthcare offers a peer-to-peer review where your prescriber can discuss the case directly with a UnitedHealthcare medical director. If the denial stands, formal pre-service appeals are available, with expedited processing for serious health risks. Post-service claim denials follow a two-step process: a claim reconsideration, then an appeal if the reconsideration is denied. The full process must be completed within 12 months.12UHC Provider. Appeals

If coverage still isn’t available, the federal TrumpRx platform offers direct-to-consumer pricing outside insurance. Under deals announced with Novo Nordisk and Eli Lilly, Ozempic and Wegovy are available for $350 per month, down from roughly $1,000 to $1,350, and Zepbound averages $346 per month, down from about $1,086.13AJMC. Trump Announces Deals With Eli Lilly, Novo Nordisk for Lower Weight Loss Drug Prices Future oral GLP-1 pills from either manufacturer will be priced at $150 per month on the platform.14MobiHealthNews. White House Partners Lilly, Novo Nordisk TrumpRx This route doesn’t change what your UnitedHealthcare plan covers, but it gives members whose plans exclude weight-loss drugs an alternative well below retail.